Avastin Reimbursement Worry Drives Patient Petition To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Fueled by a teen on Facebook whose mom has breast cancer, grassroots campaign aims to keep Avastin as a treatment option, but NCCN may carry as much weight as FDA.
You may also be interested in...
Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA
FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.
Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA
FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval
Although Pfizer's voluntary withdrawal of its acute myeloid leukemia therapy Mylotarg is the first complete withdrawal of an accelerated approval NDA, but as in other cases where the confirmatory trial fails to substantiate the initial signs of efficacy that supported the accelerated approval, FDA is not completely closing the door on access to the drug